Active
TERM 1
March 3, 2025 · 408 days ago
🌐 Foreign Policy
On March 3, 2025, President Trump signed Executive Order 14228, further amending duties addressing the synthetic opioid supply chain originating from China. The order modifies existing tariff or enforcement mechanisms related to Chinese opioid precursors and related materials. Confirmed direct impacts on Americans include altered costs for pharmaceutical inputs and potential effects on opioid treatment medication availability and pricing.
Active
TERM 1
February 5, 2025 · 434 days ago
💰 Economy
Executive Order 14200 was signed on February 5, 2025, amending duties and enforcement mechanisms related to synthetic opioid supply chains from China. The order modifies existing tariff and import protocols for substances and precursors identified as contributors to opioid trafficking. The confirmed direct impact includes changes to customs enforcement procedures and potential alterations to import costs for pharmaceutical and chemical manufacturers sourcing from China.
Active
TERM 1
February 1, 2025 · 438 days ago
🌐 Foreign Policy
Executive Order 14195 was signed on February 1, 2025, directing the imposition of duties on synthetic opioids and precursor chemicals sourced from China. The order establishes tariffs and trade restrictions on these substances to disrupt supply chains. The confirmed direct impact includes increased costs for pharmaceutical manufacturers and potential effects on opioid medication availability and pricing for Americans.
In the Courts
TERM 1
July 24, 2020 · 2,091 days ago
🏥 Healthcare
Executive Order 13939 was signed on July 24, 2020, directing the Department of Health and Human Services to issue a safe harbor rule removing anti-kickback protections for rebates in drug pricing negotiations. The order aimed to increase price transparency by allowing pharmaceutical manufacturers, pharmacy benefit managers, and health plans to negotiate rebates directly. The confirmed effect was that HHS issued a proposed rule in January 2021 to modify anti-kickback statute safe harbors, though implementation faced legal challenges and the rule's real-world impact on patient drug prices remained subject to ongoing litigation.
Active
TERM 1
May 16, 2019 · 2,526 days ago
💰 Economy
On May 16, 2019, President Trump signed Proclamation 9761 removing India from the list of beneficiary developing countries under the Generalized System of Preferences (GSP) program established by the Trade Act of 1974. The proclamation eliminated India's duty-free access to U.S. markets for approximately 2,000 product categories, effective June 5, 2019. Indian exporters faced tariffs on products previously entering the U.S. duty-free, affecting American importers and consumers of goods including pharmaceuticals, chemicals, and textiles.